Voclosporin - Aurinia Pharmaceuticals

Drug Profile

Voclosporin - Aurinia Pharmaceuticals

Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; Orelvo; R-1524; Voclera

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isotechnika
  • Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Paladin Labs
  • Class Anti-inflammatories; Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lupus nephritis
  • Phase II Focal segmental glomerulosclerosis
  • Phase I Nephrotic syndrome
  • No development reported Renal transplant rejection
  • Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 25 Sep 2018 Aurinia Pharmaceuticals completes enrolment in the phase III AURORA trial for Lupus nephritis in USA, Spain, Bulgaria, Argentina, Belarus, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Japan, South Korea, Macedonia, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Puerto Rico, Russia, Serbia, South Africa, Taiwan, Thailand, Turkey, Ukraine and Vietnam (PO)
  • 21 Jun 2018 Phase-II clinical trials in Focal segmental glomerulosclerosis (Treatment-naive) in USA(PO) (NCT03598036)
  • 10 May 2018 Phase-I clinical trials in Focal segmental glomerulosclerosis in Canada (PO) (Aurinia Pharmaceuticals pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top